FINLAND: FIMEA requires on-site monitoring reduction during COVID-19 emergency

By Published On: March 13th, 20201.1 min read
Categories: Eastern Europe, Europe

FINLAND: FIMEA requires on-site monitoring reduction during COVID-19 emergency

By Published On: March 13th, 20201.1 min read
Categories: Eastern Europe, Europe

Fimea provided guidance on trial monitoring plans during COVID-19 emergency.

Meditrial manages several studies in Finland and has direct connections with Investigators, hospitals and local Ethics Committees. Please feel free to contact us for advice and support.

Monitoring activity

Sponsors are recommended to remotely monitor studies as much as possible (e.g. centralized monitoring). Deviation from the original monitoring plan to be documented and, in some cases, notified for protocol change.

More info can be requested via email.

For more details, please see a translated version of the original guideline.

Meditrial can help – Contact us for immediate support

Meditrial has developed rapid workflows to conduct a risk assessment, implement rescue plans and execute solutions for ongoing clinical trials:

Contact Meditrial for immediate assistance in Europe or the US.

Table of Contents

Latest Articles

This article provides general information and does not constitute regulatory, legal, clinical, or compliance advice. Requirements and appropriate processes may vary by study, product, jurisdiction, and organization. Medigen Suite functionality should be used in accordance with applicable regulations, study documentation, and internal procedures.

Go to Top